Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Maitra, Arundhati; Bates, Sad��; Shaik, Monisha; Evangelopoulos, Dimitrios; Abubakar, Ibrahim; McHugh, Timothy D.; Lipman, Marc; Bhakta, Sanjib (2016)
Publisher: Oxford University Press
Languages: English
Types: Article
Subjects: bcs, Invited Review
Introduction \ud The number of cases of drug-resistant Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), has risen rapidly in recent years. This has led to the resurgence in repurposing existing drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), for anti-TB treatment. \ud Sources of data\ud Evidence from novel drug screening in vitro, in vivo, pharmacokinetic/pharmacodynamics analyses and clinical trials has been used for the preparation of this systematic review of the potential of NSAIDs for use as an adjunct in new TB chemotherapies. \ud Areas of agreement\ud Certain NSAIDs have demonstrated inhibitory properties towards actively-replicating, dormant and drug-resistant clinical isolates of M. tuberculosis cells. \ud Areas of controversy \ud NSAIDs are a diverse class of drugs, which have reported off-target activities and their endogenous antimicrobial mechanism(s) of action is still unclear. \ud Growing points \ud It is essential that clinical trials of NSAIDs continue, in order to assess their suitability for addition to the current TB treatment regimen. Repurposing molecules such as NSAIDs is a vital, low-risk strategy to combat the trend of rapidly increasing antibiotic resistance.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Organization WH. Global tuberculosis report 2015. 2015
    • Burman WJ. Rip Van Winkle Wakes Up: Development of Tuberculosis Treatment in the 21st Century. Clinical Infectious Diseases 2010; 50: S165-S172
    • Maitra A, Bhakta S. TB Summit 2014: prevention, diagnosis, and treatment of tuberculosis-a meeting report of a Euroscicon conference. Virulence 2014; 5: 638-44 Maitra A, Danquah CA, Scotti F et al. Tackling tuberculosis: Insights from an international TB Summit in London. Virulence 2015; 6: 581-92
    • Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29-40 Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006; 25: 420-8
    • Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004; 3: 673-83
    • Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013; 12: 388-404
    • Languillon J. The effects ot thalidomide on leprosy reaction. International Journal of Leprosy 1971; 39: 590-592
    • Schoeman JF, Fieggen G, Seller N, Mendelson M, Hartzenberg B. Intractable Intracranial Tuberculous Infection Responsive to Thalidomide: Report of Four Cases. Journal of Child Neurology 2006; 21: 301-308
    • Oprea TI, Mestres J. Drug repurposing: far beyond new targets for old drugs. AAPS J 2012; 14: 759-63
    • Kinnings SL, Xie L, Fung KH, Jackson RM, Bourne PE. The Mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comput Biol 2010; 6: e1000976 Palomino JC, Martin A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis? J Antimicrob Chemother 2013; 68: 275-83
    • Gillespie SH, Crook AM, McHugh TD et al. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. New England Journal of Medicine 2014 Maitra A, Bates S, Kolvekar T et al. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis. Int J Infect Dis 2015; 32: 50-5
    • Amaral L, Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int J Antimicrob Agents 2012; 39: 376- 80
    • Gupta S, Cohen KA, Winglee K et al. Efflux Inhibition with Verapamil Potentiates Bedaquiline in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 2014; 58: 574-576 Maiga M, Ammerman NC, Maiga MC et al. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis 2013; 208: 512-9
    • Gold B, Pingle M, Brickner SJ et al. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A 2012; 109: 16004-11
    • Guzman JD, Evangelopoulos D, Gupta A et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open 2013; 3
    • Ivanyi J, Zumla A. Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment. J Infect Dis 2013; 208: 185-8
    • Lee YT, Wang Q. Inhibition of hKv2.1, a major human neuronal voltage-gated K+ channel, by meclofenamic acid. Eur J Pharmacol 1999; 378: 349-56
  • Inferred research data

    The results below are discovered through our pilot algorithms. Let us know how we are doing!

    Title Trust
  • No similar publications.

Share - Bookmark

Funded by projects

  • WT

Cite this article